Arcturus and CF Foundation extend pact to advance ARCT-032

Arcturus Therapeutics Holdings announced that Arcturus and the Cystic Fibrosis Foundation CF Foundation have extended their ongoing agreement. The CF Foundation agreed to increase its financial commitment to ~$25M to advance ARCT-032, a novel messenger RNA mRNA therapeutic candidate formulated with Arcturus’ LUNAR delivery technology. This agreement extends a prior research program, initiated in 2017, which has resulted in the advancement of ARCT-032 into ongoing clinical studies. “We are thrilled to extend our productive relationship with the Cystic Fibrosis Foundation, and we are grateful for their meaningful financial support,” said Pad Chivukula, Ph.D., Chief Scientific Officer of Arcturus. “ARCT-032 has the potential to express fully functional CFTR protein in the lung, thereby addressing the root cause of cystic fibrosis. The resources and valuable expertise provided by the CF Foundation will support the continued clinical development of ARCT-032, including the completion of a Phase 1b study that we plan to initiate imminently in adults living with cystic fibrosis.”